ECSP22083926A - Compuestos útiles para inhibir la quinasa ret - Google Patents

Compuestos útiles para inhibir la quinasa ret

Info

Publication number
ECSP22083926A
ECSP22083926A ECSENADI202283926A ECDI202283926A ECSP22083926A EC SP22083926 A ECSP22083926 A EC SP22083926A EC SENADI202283926 A ECSENADI202283926 A EC SENADI202283926A EC DI202283926 A ECDI202283926 A EC DI202283926A EC SP22083926 A ECSP22083926 A EC SP22083926A
Authority
EC
Ecuador
Prior art keywords
ret kinase
compounds useful
inhibiting ret
ret
inhibiting
Prior art date
Application number
ECSENADI202283926A
Other languages
English (en)
Inventor
Thomas C Irvin
Kevin R Condroski
michael b Welch
Gabrielle R Kolakowski
Michael J Munchhof
Erin D Anderson
Elizabeth A Mcfaddin
Manoj Kumar
Steven W Andrews
Megan L Mckenney
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP22083926A publication Critical patent/ECSP22083926A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38Nitrogen atoms
    • C07D231/40Acylated on said nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En la presente se proporcionan inhibidores de la quinasa RET de acuerdo con la fórmula (I): sales aceptables desde el punto de vista farmacéutico de estos, composiciones farmacéuticas de estos y métodos para su uso en el tratamiento de enfermedades que pueden tratarse con un inhibidor de la quinasa RET, incluidas enfermedades y trastornos asociados a RET. A, R1, n, X1, X2, X3, X4, y R2 tienen los significados dados en la memoria descriptiva.
ECSENADI202283926A 2020-04-27 2022-10-27 Compuestos útiles para inhibir la quinasa ret ECSP22083926A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063015933P 2020-04-27 2020-04-27

Publications (1)

Publication Number Publication Date
ECSP22083926A true ECSP22083926A (es) 2022-11-30

Family

ID=75914595

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202283926A ECSP22083926A (es) 2020-04-27 2022-10-27 Compuestos útiles para inhibir la quinasa ret

Country Status (18)

Country Link
US (2) US11613533B2 (es)
EP (1) EP4143184A1 (es)
JP (1) JP7441972B2 (es)
KR (1) KR20230005301A (es)
CN (1) CN115667253A (es)
AR (1) AR121914A1 (es)
AU (1) AU2021263541B2 (es)
BR (1) BR112022021735A2 (es)
CA (1) CA3177080A1 (es)
CL (1) CL2022003000A1 (es)
CO (1) CO2022016013A2 (es)
DO (1) DOP2022000234A (es)
EC (1) ECSP22083926A (es)
IL (1) IL297551B2 (es)
MX (1) MX2022013482A (es)
PE (1) PE20230780A1 (es)
TW (1) TWI777509B (es)
WO (1) WO2021222017A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20231984A1 (es) * 2020-11-06 2023-12-12 Lilly Co Eli Derivados de pirazol como inhibidores de la ret-cinasa

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201524958A (zh) * 2013-03-15 2015-07-01 Glaxosmithkline Ip Dev Ltd 用作轉染期間重排抑制劑之新穎化合物
WO2017145050A1 (en) * 2016-02-23 2017-08-31 Glaxosmithkline Intellectual Property Development Limited Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer
US10183928B2 (en) * 2016-03-17 2019-01-22 Blueprint Medicines Corporation Inhibitors of RET
WO2020035065A1 (zh) * 2018-08-17 2020-02-20 南京明德新药研发有限公司 作为ret抑制剂的吡唑衍生物

Also Published As

Publication number Publication date
DOP2022000234A (es) 2022-11-30
AU2021263541A1 (en) 2022-11-24
JP2023523315A (ja) 2023-06-02
IL297551B2 (en) 2024-06-01
BR112022021735A2 (pt) 2022-12-06
EP4143184A1 (en) 2023-03-08
IL297551B1 (en) 2024-02-01
US11964968B2 (en) 2024-04-23
CL2022003000A1 (es) 2023-06-23
PE20230780A1 (es) 2023-05-09
CA3177080A1 (en) 2021-11-04
US20230312544A1 (en) 2023-10-05
JP7441972B2 (ja) 2024-03-01
CN115667253A (zh) 2023-01-31
MX2022013482A (es) 2022-11-16
WO2021222017A1 (en) 2021-11-04
US11613533B2 (en) 2023-03-28
AU2021263541B2 (en) 2024-03-07
AR121914A1 (es) 2022-07-20
TWI777509B (zh) 2022-09-11
TW202206428A (zh) 2022-02-16
US20210363140A1 (en) 2021-11-25
IL297551A (en) 2022-12-01
KR20230005301A (ko) 2023-01-09
CO2022016013A2 (es) 2022-11-18

Similar Documents

Publication Publication Date Title
CL2021000382A1 (es) Compuestos novedosos de sulfonamidaurea
CO2023008167A2 (es) Inhibidores de prmt5
CL2019002777A1 (es) Compuestos que inhiben la proteína mcl-1.
DOP2019000091A (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
CR20190218A (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
CO2023007504A2 (es) Derivados de carboxamida tricíclica como inhibidores de prmt5
CO2022015638A2 (es) Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso
CO6290687A2 (es) Inhibidores de cinasa pim y metodos para su uso
UY30298A1 (es) Inhibidores de la quinasa c-fms ii
BR112017017135A2 (pt) inibidores de tgf-beta
AR063098A1 (es) Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina
UY30912A1 (es) Derivados de 4-pirazol amidas conteniendo carboxi, sales farmacéuticamente aceptables de los mismo, composiciones farmacéuticas conteniéndolos, procesos de preparacion y uso.
DOP2019000184A (es) Inhibidores selectivos de jak1
ECSP066349A (es) Inhibidores de transferasa de proteína de farnesilo novedosos como agentes antitumorales
AR085308A1 (es) Formas solidas del inhibidor de girasa (r)-1-etil-3-[6-fluoro-5-[2-(1-hidroxi-1-metil-etil)pirimidin-5-il]-7-(tetrahidrofuran-2-il)-1h-benzimidazol-2-il]urea
ECSP22083926A (es) Compuestos útiles para inhibir la quinasa ret
CL2022001741A1 (es) Compuestos cíclicos y métodos de uso de estos
CL2022003812A1 (es) Inhibidores de rip1k
AR128500A1 (es) Inhibidores de arn helicasa dhx9 y usos de los mismos
CO2024000565A2 (es) Inhibidores del inflamasoma nlrp3
ECSP23070418A (es) Moduladores de sting (estimulador de genes de interferón)
AR127561A1 (es) Compuestos para el tratamiento de trastornos dependientes de cinasas
CO2022000118A2 (es) Inhibidores de jak cinasas basados en pirazolopirimidina sulfona y usos de los mismos
UY38133A (es) Nuevos inhibidores de cdk8/19
ECSP23075535A (es) Compuestos cíclicos y métodos de uso